3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
292
Urinary Bladder Neoplasms
39
Neoplasm Metastasis
35
Carcinoma, Non-Small-Cell Lung
24
Carcinoma, Transitional Cell
23
Neoplasms
21
Breast Neoplasms
20
Lung Neoplasms
13
Carcinoma, Renal Cell
13
Ovarian Neoplasms
12
Stomach Neoplasms
11
Squamous Cell Carcinoma of Head and Neck
11
Non-Muscle Invasive Bladder Neoplasms
10
Melanoma
9
Small Cell Lung Carcinoma
7
Salivary Gland Neoplasms
7
Prostatic Neoplasms, Castration-Resistant
7
Head and Neck Neoplasms
7
Esthesioneuroblastoma, Olfactory
7
Esophageal Neoplasms
7
Colorectal Neoplasms
7
Urethral Neoplasms
6
Uterine Cervical Neoplasms
5
Triple Negative Breast Neoplasms
5
Prostate Cancer Metastatic
5
Pancreatic Neoplasms
5
Metastatic Castration-resistant Prostate Cancer
5
Kidney Neoplasms
5
Adenocarcinoma
5
Sarcoma
4
Interventions
Androgen Antagonists
3
darolutamide
2
Docetaxel
2
relugolix
1
niraparib
1
Prednisone
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
×
Docetaxel
×
Genitourinary
×
Clear all
NCT06661122
2026-05-19
HAYATE
Bayer
Recruiting
100 enrolled
NCT06392841
2026-04-08
HARMONY
Hoosier Cancer Research Network
Phase 2
Withdrawn